Kymera Therapeutics (KYMR) AI Stock Analysis

• Market Cap: $5.52B
• Dividend Yield: N/A
• Average Volume (3M): 700.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.01
• Revenue Growth: -50.05%
• EPS Growth: -54.47%
• Country: US
• Employees: 208
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.94
• Shares Outstanding: 78,949,030
• 10 Day Avg. Volume: 589,702
• 30 Day Avg. Volume: 700,008
• PEG Ratio: -0.74
• Price to Book (P/B): 3.61
• Price to Sales (P/S): 64.14
• P/FCF Ratio: -14.56
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 127.62
• Enterprise Value/Gross Profit: -172.02
• Enterprise Value/Ebitda: -19.52
• 1Y Price Target: $116.30
• Price Target Upside: 66.31% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 22
• EPS Forecast (FY): -3.67
• Revenue Forecast (FY): $47.38M

• Rating: 50 Neutral
• Price Target: $73.00 ▲(4.39% Upside)

The score is held down primarily by weak financial performance (ongoing losses, declining revenue trend, and deeply negative operating/free cash flow). Offsetting this is a relatively strong earnings-call profile with clear clinical milestones and a sizable cash runway, while technicals are mixed and valuation is constrained by negative earnings and no dividend support.

Positive Factors

Strong Financial Position

A robust cash position ensures Kymera can fund its R&D and operational needs without immediate financial pressure, supporting long-term growth.

Strategic Partnerships

Partnerships with major pharma companies like Gilead enhance Kymera's research capabilities and market reach, crucial for long-term success.

Pipeline Expansion

Expanding the pipeline with new candidates diversifies risk and increases the potential for future revenue streams, supporting sustainable growth.

Negative Factors

Declining Revenue

Declining revenue trends highlight challenges in monetizing products, which can hinder long-term financial stability and growth prospects.

High Operational Costs

High operational costs can strain financial resources, reducing the company's ability to invest in growth initiatives and impacting profitability.

Negative Cash Flow

Negative cash flow indicates challenges in generating sufficient cash from operations, which can limit financial flexibility and long-term viability.

Kymera Therapeutics Business Overview & Revenue Model

Company Description

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

Kymera Therapeutics generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which provide funding for the development of its drug candidates. The company may receive upfront payments, research funding, and milestone payments as its products progress through various stages of development. Additionally, Kymera could earn royalties on future sales of any approved therapies stemming from these collaborations. The company's revenue model is heavily reliant on the successful advancement of its therapeutic candidates in clinical trials and the establishment of strategic alliances to enhance its research capabilities and market reach.

Kymera Therapeutics Financial Statement Overview

Summary

Weak fundamentals overall: declining TTM revenue growth (-2.19%), persistent losses (TTM net margin -6.75%) and negative EBIT/EBITDA margins. Cash flow is a key risk with deeply negative operating/free cash flow (TTM OCF -$227.93M; FCF -$230.21M) and negative FCF growth (-8.98%). Balance sheet leverage is conservative (debt-to-equity 0.09), but profitability remains poor (ROE -33.35%).

Income Statement

Kymera Therapeutics shows a declining revenue trend with a negative revenue growth rate of -2.19% in the TTM period. The company has consistently negative net profit margins, with a TTM net profit margin of -6.75%, indicating ongoing losses. The EBIT and EBITDA margins are also negative, reflecting operational challenges. Overall, the income statement indicates financial instability and a need for strategic improvements to reverse the negative trends.

Balance Sheet

The balance sheet of Kymera Therapeutics shows a relatively low debt-to-equity ratio of 0.09 in the TTM period, suggesting conservative leverage. However, the return on equity is negative at -33.35%, indicating that the company is not generating profits from its equity base. The equity ratio is not explicitly provided, but the company maintains a solid equity base relative to its assets. While the low leverage is a positive aspect, the negative ROE highlights profitability issues.

Cash Flow

Kymera Therapeutics has negative operating and free cash flows, with a TTM operating cash flow of -$227.93 million and free cash flow of -$230.21 million. The free cash flow growth rate is negative at -8.98%, indicating worsening cash flow conditions. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. The cash flow statement underscores the company's struggle to generate positive cash flows, posing a risk to financial sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	43.73M	47.07M	78.59M	46.83M	72.83M	34.03M
Gross Profit	-32.44M	47.07M	78.59M	46.83M	72.83M	34.03M
EBITDA	-285.92M	-216.24M	-143.20M	-151.66M	-97.64M	-43.72M
Net Income	-295.12M	-223.86M	-146.96M	-154.81M	-100.22M	-45.59M
Balance Sheet
Total Assets	1.10B	978.03M	575.76M	603.13M	605.90M	487.18M
Cash, Cash Equivalents and Short-Term Investments	505.68M	488.74M	374.88M	407.17M	442.42M	296.20M
Total Debt	84.00M	87.76M	84.67M	17.34M	17.96M	17.99M
Total Liabilities	155.79M	142.42M	180.79M	112.98M	146.27M	203.29M
Stockholders Equity	946.26M	835.62M	394.97M	490.15M	459.64M	283.89M
Cash Flow
Free Cash Flow	-230.21M	-207.34M	-137.31M	-155.92M	-130.54M	79.03M
Operating Cash Flow	-227.93M	-194.50M	-102.83M	-153.09M	-128.95M	88.13M
Investing Cash Flow	-58.09M	-404.08M	139.89M	20.52M	-99.83M	-422.59M
Financing Cash Flow	288.26M	608.85M	4.19M	153.00M	250.28M	289.26M

Kymera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 69.93
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYMR, the sentiment is Negative. The current price of 69.93 is below the 20-day moving average (MA) of 74.52, below the 50-day MA of 73.98, and above the 200-day MA of 51.57, indicating a neutral trend. The MACD of -1.54 indicates Positive momentum. The RSI at 42.58 is Neutral, neither overbought nor oversold. The STOCH value of 43.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KYMR.

Kymera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRNX	64 Neutral	$5.45B	-11.73	-44.42%	―	―	-21.96%
PTGX	61 Neutral	$5.20B	131.20	7.80%	―	-35.39%	-72.97%
MLTX	55 Neutral	$1.13B	-4.77	-54.17%	―	―	-157.74%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APLS	50 Neutral	$2.75B	73.26	14.10%	―	42.11%	―
KYMR	50 Neutral	$5.52B	―	-32.09%	―	-50.05%	-54.47%

Kymera Therapeutics Corporate Events

Kymera Therapeutics Sets 2026 Clinical Strategy and Milestones

On January 13, 2026, Kymera Therapeutics outlined its 2026 objectives and clinical strategy, highlighting progress and upcoming milestones across its oral immunology pipeline, including the STAT6 degrader KT-621 and the IRF5 degrader KT‑579. The company reported that in December 2025 KT-621 produced positive Phase 1b data in moderate to severe atopic dermatitis patients, showing deep STAT6 degradation, robust biomarker reductions and meaningful clinical improvements that were in line with or numerically exceeded four-week dupilumab data, and the asset received FDA Fast Track designation that same month. KT-621 is now in Phase 2b development, with the BROADEN2 trial in atopic dermatitis dosing since November 2025 and recently expanded to include adolescents, and the BREADTH Phase 2b trial in eosinophilic asthma initiated in January 2026, with both studies expected to deliver data in 2027. Kymera has completed IND-enabling studies for KT-579, which demonstrated strong efficacy and clean safety in preclinical lupus and rheumatoid arthritis models, and plans to start a first-in-human Phase 1 healthy volunteer trial in the first quarter of 2026 with data anticipated in the second half of 2026. Additional pipeline momentum comes from partnered programs such as the IRAK4 degrader KT-485/SAR447971 with Sanofi, expected to enter Phase 1 in 2026, and an oral CDK2 molecular glue oncology program under an exclusive option and license agreement with Gilead, while Kymera also plans to advance at least one new first-in-class oral immunology candidate toward IND this year, underscoring its ambition to reshape treatment standards and consolidate its position as a leading player in oral immunology therapeutics.

The most recent analyst rating on (KYMR) stock is a Buy with a $138.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Kymera Therapeutics Announces Major Stock Offering

On December 9, 2025, Kymera Therapeutics announced an underwritten public offering of 7,000,000 shares of its common stock at $86.00 per share, expected to close on December 11, 2025. The company anticipates net proceeds of approximately $656.1 million, which will be used to advance its degrader programs and for general corporate purposes. The offering, managed by major financial institutions, includes an option for underwriters to purchase an additional 1,050,000 shares. This move is expected to support Kymera’s operations into 2029, enhancing its market position and stakeholder value.

The most recent analyst rating on (KYMR) stock is a Buy with a $125.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Kymera Therapeutics Unveils Promising Phase 1b Trial Results

On December 8, 2025, Kymera Therapeutics discussed the results of their Phase 1b trial for KT-621, an oral STAT6 degrader, in atopic dermatitis patients. The trial’s outcomes are significant as they highlight the potential of KT-621 to transform treatment options for atopic dermatitis and other Type 2 inflammatory diseases, positioning Kymera as a key player in the immunology market.

The most recent analyst rating on (KYMR) stock is a Buy with a $98.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Kymera Therapeutics Announces Positive Phase 1b Trial Results

On December 8, 2025, Kymera Therapeutics announced positive results from their BroADen Phase 1b clinical trial of KT-621, an oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The trial demonstrated significant STAT6 degradation and reductions in Type 2 inflammatory biomarkers, with KT-621 showing promising clinical activity and safety profile. These results suggest KT-621’s potential as a first-in-class oral treatment for Type 2 inflammatory diseases, with ongoing and planned trials aiming to further its development.

The most recent analyst rating on (KYMR) stock is a Buy with a $98.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.